Publications by authors named "Elena Derkach"
Background: In Russia, before 2022, the list of vital and essential drugs for HIV-infected patients previously untreated with antiretroviral drugs included the fixed-dose combination rilpivirine/tenofovir disoproxil fumarate/emtricitabine (RPV/TDF/FTC) but not doravirine/tenofovir disoproxil fumarate/lamivudine (DOR/TDF/3TC).
Methods: An indirect comparison of the efficacy of DOR/TDF/3TC and RPV/TDF/FTC defined by virologic suppression (HIV-1 RNA of <50 copies/mL at week 48) was made. The per-patient drug costs over 1 year were compared in a cost-minimization analysis.
Article Synopsis
- Malignant tumors of the gallbladder are uncommon, with adenocarcinoma as the most prevalent type, while carcinosarcoma is an extremely rare variant that accounts for less than 1% of gallbladder cancers.
- Carcinosarcoma can occur in various organs, but it is typically found in the uterus, and its diagnosis is challenging due to its unique combination of epithelial and mesenchymal components.
- As there have been fewer than 100 cases documented in English literature, this article aims to enhance awareness among healthcare professionals to improve diagnosis, treatment, and survival rates for patients with this rare condition.
The paper proposes a game-theoretic model of interaction between investors and innovators, taking into account the existence of so-called "fake" innovators offering knowingly unprofitable projects. The model is a Bayesian non-cooperative, repetitive game with recalculated payments and partly unobservable player types. It allows quantifying the parameters of the strategy for all player types to find equilibrium solutions.
View Article and Find Full Text PDFThe Cost of Melanoma and Kidney, Prostate, and Ovarian Cancers in Russia.
Value Health Reg Issues
September 2014
Objective: The objective of this study was to assess the total annual economic burden of melanoma and kidney, prostate, and ovarian cancers in Russia using the unified methods.
Methods: The general prevalence-based cost-of-illness model was developed to evaluate the annual health and social care costs and value of lost productivity attributable to the following cancers: melanoma and kidney, prostate, and ovarian cancers from the perspective of the overall governmental budget. All costs were calculated using the "bottom-up" costing technique for the total population of patients with studied cancer, including both newly diagnosed patients stratified by cancer stage and patients diagnosed in previous years who were still alive in the study year.